L Ryvo

738 citations

8 papers · 544 indexed · 1 hit paper · h-index 5

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Cancer Research
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies

Papers in ⓘ

Pulmonary and Respiratory Medicine 7
- Advanced Breast Cancer Therapies 6
Oncology 5
- Cancer Treatment and Pharmacology 3
- Cancer Immunotherapy and Biomarkers 2

Co-authors: Sylvia Adams (2 shared papers)Rita Nanda (2 shared papers)Antoinette R. Tan (2 shared papers)Kenji Tamura (2 shared papers)Vassiliki Karantza (2 shared papers)Hiroji Iwata (4 shared papers)Peter Schmid (2 shared papers)Michelino De Laurentiis (2 shared papers)
Journals: Cancer Research (4 papers)Annals of Oncology (2 papers)Journal of Geriatric Oncology (1 paper)Breast Care (1 paper)
Partner nations: Israel Japan United States

In The Last Decade

L Ryvo

8 papers receiving 537 citations

Hit Papers

align trajectories log scale

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study 2018 · 460 citations

Peers

Countries citing papers authored by L Ryvo

Since Specialization

Citations

This map shows the geographic impact of L Ryvo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Ryvo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Ryvo more than expected).

Fields of papers citing papers by L Ryvo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Ryvo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Ryvo. The network helps show where L Ryvo may publish in the future.

Co-authors

The 25 scholars most cited alongside L Ryvo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with L Ryvo Line = papers co-authored together L Ryvo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work
1	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Annals of Oncology ·Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michelino De Laurentiis, Rita Nanda, Eric P. Winer, Hirofumi Mukai, Kenji Tamura, Anne Armstrong, M.C. Liu, Hiroji Iwata, L Ryvo, Pauline Wimberger, Hope S. Rugo, Antoinette R. Tan, Lin Jia, Yu Ding, Vassiliki Karantza, Peter Schmid Hit paper breakdown →	2018	460
2	Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway Breast Care ·Shira Peleg Hasson, Tamar Rubinek, L Ryvo, Ido Wolf	2013	39
3	Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) Cancer Research ·Sylvia Adams, Sherene Loi, D. Toppmeyer, DW Cescon, Michelino De Laurentiis, Rita Nanda, EP Winer, Hirofumi Mukai, Kenji Tamura, AC Armstrong, MC Liu, Hiroji Iwata, L Ryvo, Pauline Wimberger, HS Rugo, Antoinette R. Tan, C D'Aquanno, Yi Ding, Vassiliki Karantza, Peter Schmid	2018	22
4	Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98% Cancer Research ·Salomon M. Stemmer, M. Steiner, Shulamith Rizel, Lior Soussan‐Gutman, D. Geffen, Bella Nisenbaum, Noa Ben-Baruch, Kim L. Isaacs, Georgeta Fried, Ora Rosengarten, Beatrice Uziely, Cecilia Svedman, Megan Rothney, SH Klang, L Ryvo, Bella Kaufman, Ella Evron, Jamal Zidan, Steven Shak, Nicky Liebermann	2016	15
5	Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study Cancer Research ·Tamar Safra, Bella Kaufman, Baruch N Ben, L Kadouri-Sonenfeld, Bella Nisenbaum, Joel Greenberg, L Ryvo, Rinat Yerushalmi, Ella Evron	2012	4
6	A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) Annals of Oncology ·Fabrice André, Bella Kaufman, Dejan Juric, Eva Ciruelos, Hiroji Iwata, Ingrid A. Mayer, Pierfranco Conté, Hope S. Rugo, Sibylle Loibl, Gábor Rubovszky, Hans Tesch, Kenichi Inoue, Yen‐Shen Lu, L Ryvo, A.-S. Longin, David Mills, C. Wilke, Caroline Germa, Mario Campone	2016	2
7	Recurrence score results in elderly patients with estrogen receptor positive early breast cancer Journal of Geriatric Oncology ·M. Steiner, N.B. Ciuraru, Bella Nisenbaum, L Ryvo, Beatrice Uziely, David Geffen, Karen Drumea, Michelle Leviov, Shulamith Rizel, Salomon M. Stemmer	2013	1
8	Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy Cancer Research ·Fabrice André, Bella Kaufman, Dejan Juric, Eva Ciruelos, Hiroji Iwata, IA Mayer, HS Rugo, Pierfranco Conté, S Liobl, Gábor Rubovszky, Kenichi Inoue, Hans Tesch, Yen‐Shen Lu, L Ryvo, A.-S. Longin, David Mills, C. Wilke, Caroline Germa, Mario Campone	2017	1

About L Ryvo

L Ryvo is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Biotechnology and Molecular Biology, having authored 8 papers that have together received 544 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (6 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Cancer Treatment and Pharmacology (3 papers), Breast Cancer Treatment Studies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Neuroendocrine Tumor Research Advances (1 paper), Medical Imaging Techniques and Applications (1 paper) and Estrogen and related hormone effects (1 paper). The work is most often cited by research in Oncology (462 citations), Cancer Research (140 citations), Immunology (167 citations), Pulmonary and Respiratory Medicine (173 citations) and Molecular Biology (95 citations). L Ryvo has collaborated with scholars based in Israel, Japan and United States. Frequent co-authors include Sylvia Adams, Rita Nanda, Antoinette R. Tan, Kenji Tamura, Vassiliki Karantza, Hiroji Iwata, Peter Schmid, Michelino De Laurentiis, Hirofumi Mukai and Sherene Loi. Their work appears in journals such as Cancer Research, Annals of Oncology, Journal of Geriatric Oncology and Breast Care.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact